PDL Biopharma (NASDAQ:PDLI) has earned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.50.
A number of analysts have recently issued reports on PDLI shares. BidaskClub raised shares of PDL Biopharma from a “strong sell” rating to a “sell” rating in a research note on Friday, March 9th. Zacks Investment Research raised shares of PDL Biopharma from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research note on Wednesday, March 14th. TheStreet raised shares of PDL Biopharma from a “d+” rating to a “c-” rating in a research note on Friday, March 9th. Finally, ValuEngine raised shares of PDL Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th.
Shares of PDLI stock traded down $0.01 during midday trading on Friday, hitting $2.97. 338,970 shares of the stock were exchanged, compared to its average volume of 1,533,239. The company has a current ratio of 3.32, a quick ratio of 3.10 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $455.28, a PE ratio of 4.14 and a beta of 0.58. PDL Biopharma has a 1 year low of $1.96 and a 1 year high of $3.55.
TRADEMARK VIOLATION NOTICE: This story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3293569/pdl-biopharma-pdli-receives-average-rating-of-hold-from-brokerages.html.
PDL Biopharma Company Profile
PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.
Receive News & Ratings for PDL Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.